FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Grigoriadis Dimitri E. (Last) (First) (Middle) NEUROCRINE BIOSCIENCES, INC. 12780 EL CAMINO REAL (Street) SAN DIEGO CA 92130						2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX] 3. Date of Earliest Transaction (Month/Day/Year) 01/10/2013 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director				
(City)) (State) (Zip)					ı												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transar Date (Month/Da						ear)	2A. Deemo Execution if any (Month/Da	Date	Code (Ir			ties Acquired (A) or I Of (D) (Instr. 3, 4 and		5. Amour Securitie Beneficia Owned F Reported	s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)	Price	Transact	ansaction(s) 1str. 3 and 4)			,	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,	1. Fransa Code (I 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and of Security Underlying Derivative (Instr. 3 and	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		expiration Date	Title	Amount or Number of Shares					
Stock Option ⁽¹⁾	\$8.65	01/10/2013			A		75,000		02/10/2013	0	1/10/2023	Common Stock	75,000	\$8.65	75,000		D	
Restricted Stock Units	(2)	01/10/2013			A		13,000		(3)		(3)	Common Stock	13,000	\$0	13,000)	D	

Explanation of Responses:

- 1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 10, 2013, an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- 2. Each restricted stock unit represents a contingent right to receive one share of Neurocrine Common Stock.
- 3. The restricted stock units will vest annually at 1/4 of the units vesting on January 10, 2014, January 10, 2015, January 10, 2016 and January 10, 2017, respectively.

Remarks:

Margaret E. Valeur-Jensen, By Power of Attorney

01/14/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.